EXACT Therapeutics AS – Mandatory notification of trade by primary insiders

04 Jan 2023 09:20 CET

OSLO, 4 January 2023: The following primary insiders and close associates of
primary insiders of EXACT Therapeutics AS ("Exact-Tx AS”) have on January 3,
2023 purchased shares as follows:

- Kvåle AS, a close associate of Chief Operating Officer Svein Kvåle, has
purchased 2,500 shares at NOK 12 per share. Following the purchase, Kvåle AS
holds 3,024,270 shares in Exact-Tx AS

- PAACS Invest AS, a close associate of Board Member Masha Strømme, has
purchased 2,500 shares at NOK 12 per share. Following the purchase, PAACS Invest
AS holds 2,691,509 shares in Exact-Tx AS

- Anders Wold, Chairman of the Board, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Wold holds 4,914 shares in Exact-Tx AS

- Per Walday, Chief Executive Officer, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Walday holds 2,500 shares in Exact-Tx AS and
rights to 610,643 shares.

- Amir Snapir, Chief Medical Officer, has purchased 2,500 shares at NOK 12 per
share. Following the purchase, Snapir holds 2,500 shares in Exact-Tx AS and
rights to 60,000 shares

- John M. Edminson, Chief Financial Officer, has purchased 2,500 shares at NOK
12 per share. Following the purchase, Edminson holds 2,500 shares in Exact-Tx AS
and rights to 30,000 shares

This information is subject to the disclosure requirements in Regulation EU
596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities
Trading Act.

Primary insider notifications pursuant to the EU Market Abuse Regulation Article
19 are attached hereto.

For more information, please contact:

Per Walday, CEO, per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement – Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drugtargeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site

579597_EXACT Therapeutics - Notifications of transactions by primary insiders.pdf